TYRNOVO
TyrNovo is developing NT219, a small molecule originally developed by Dr. Hadas Reuveni and Prof. Alexander Levitzki at the Hebrew University, and exclusively licensed from Yissum, the Hebrew University Research Development Company. TyrNovo demonstrated the potential of NT219 to overcome resistance to multiple anti-cancer drugs, by using the Patient-Derived Xenograft (PDX) models, in collaboration with Prof. Izhak Haviv from the Bar-Ilan University and Prof. M. Stemmer from Clalit HMO.
TYRNOVO
Industry:
Biotechnology
Address:
Herzliya, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.tyrnovo.co.il
Status:
Closed
Technology used in webpage:
Domain Not Resolving
Current Employees Featured
Founder
